Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

(2019) Yi-Long Wu et al.   Journal of Thoracic Oncology

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

(2019) Takashi Kojima et al.   JOURNAL OF CLINICAL ONCOLOGY

The emerging role of immunotherapy for esophageal cancer

(2019) Ronan J. Kelly   CURRENT OPINION IN GASTROENTEROLOGY

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

(2019) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Nasopharyngeal carcinoma

(2019) Yu-Pei Chen et al.   LANCET

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

(2019) Lu Si et al.   Translational Oncology

Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

(2019) Rui-Mei Feng et al.   Cancer Communications

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

(2019) Yuqin Song et al.   LEUKEMIA

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

(2018) Tong Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer

(2018) A. Pabani et al.   Current Oncology

Global cancer incidence in older adults, 2012 and 2035: A population-based study

(2018) Sophie Pilleron et al.   INTERNATIONAL JOURNAL OF CANCER

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

(2018) Brigette B.Y. Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries

(2018) Hongmei Zeng et al.   Lancet Global Health

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis

(2018) Bin Wang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

(2018) Paul Scorer et al.   Diagnostic Pathology

KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

(2018) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

70OA phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors

(2018) S Deva et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

(2018) Manish A. Shah et al.   JAMA Oncology

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

(2017) Chiun Hsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

(2017) Mario Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Current and emerging therapies in unresectable and recurrent gastric cancer

(2016) Erin Jou et al.   WORLD JOURNAL OF GASTROENTEROLOGY

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600

(2015) D. Massi et al.   ANNALS OF ONCOLOGY

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

(2015) Pin Wu et al.   PLoS One

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences

(2013) Bo Dai et al.   HUMAN PATHOLOGY

PD-1 as a potential target in cancer therapy

(2013) David F. McDermott et al.   Cancer Medicine

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER